GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

GlaxoSmithKline plc Sponsored ADR

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal data in advanced or relapsed small-cell lung cancer

GSK is advancing development of Ris-Rez outside China across multiple tumour types, including lung cancer, prostate cancer and other solid tumours

https://www.gsk.com/en-gb/media/press-releases/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii-trial-for-ris-rez-in-china/

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.